RCT of oral everolimus alone or with lucentis for neovascular age-related macular degeneration; results not reported
A randomised, double-masked, parallel group study designed to assess the safety and efficacy of oral everolimus (an mTOR inhibitor in the rapamycin class) alone or combined with lucentis in patients with neovascular age-related macular degeneration. No efficacy or safety results were reported in the material provided.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 19, 2011 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with neovascular age-related macular degeneration (AMD)
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Novartis Pharmaceuticals
- Published
- Aug 19, 2011
Funding: Novartis Pharmaceuticals (sponsor)
Conflicts: Study sponsored by Novartis Pharmaceuticals, manufacturer of both Everolimus (RAD001) and Lucentis
Sources
Primary source
- Novartis Pharmaceuticals ↗Clinical trial
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.